Irish medtech company Neurent Medical has taken a decisive step forward in the treatment of chronic rhinitis. On February 13, 2026, the Galway-based startup announced that it raised €62.5 million in a Series C funding round to accelerate the global expansion of its flagship product, NEUROMARK. The funding signals strong investor confidence in the company’s technology and its mission to improve the lives of millions who struggle daily with persistent nasal symptoms.
Chronic rhinitis affects a significant portion of the global population. Patients experience ongoing nasal congestion, runny nose, sneezing, and inflammation that disrupt sleep, work, and quality of life. Many rely on medications such as antihistamines, nasal sprays, or steroids, but these treatments often provide only temporary relief. Some patients undergo invasive surgical procedures when medications fail, yet they still seek better long-term solutions.
Neurent Medical has focused its innovation efforts on solving this unmet clinical need. The company developed NEUROMARK, a minimally invasive treatment designed to target the underlying nerve pathways that drive chronic rhinitis symptoms. Instead of masking symptoms, the therapy aims to address their source.
A Clear Focus on Patient-Centered Innovation
Neurent Medical built NEUROMARK to offer physicians a practical, in-office procedure that fits within existing ENT workflows. The device uses advanced radiofrequency technology to precisely target specific nerve branches in the nasal cavity. These nerves play a critical role in triggering excessive mucus production and congestion.
The company designed the treatment to deliver consistent results while maintaining patient comfort. Physicians can perform the procedure without major surgery, lengthy hospital stays, or complex recovery protocols. This focus on simplicity and efficiency has positioned NEUROMARK as an attractive option for ENT specialists who want to offer more durable relief to their patients.
The Series C funding will help Neurent Medical expand commercial operations in key markets, particularly in the United States and Europe. The company plans to invest heavily in sales infrastructure, physician training, and post-market clinical studies to support broader adoption.
Strong Investor Backing Signals Confidence
Investors in the Series C round recognized both the market opportunity and the clinical promise of NEUROMARK. Chronic rhinitis affects hundreds of millions of people worldwide. A significant percentage of these patients do not respond adequately to medication, creating a substantial demand for alternative solutions.
By raising €62.5 million, Neurent Medical secured the resources needed to accelerate its commercialization strategy. The company now has the capital to strengthen its regulatory pathways, scale manufacturing, and expand reimbursement coverage discussions with healthcare systems and insurers.
This funding round also reflects the strength of Ireland’s medtech ecosystem. Galway has built a global reputation as a hub for medical device innovation. Neurent Medical’s success adds another chapter to that story and highlights the region’s ability to produce world-class healthcare technology companies.
Expanding Beyond Early Markets
Neurent Medical already achieved important regulatory milestones in recent years. The company gained approval in the United States and launched initial commercialization efforts. With fresh capital in hand, leadership now aims to deepen market penetration and build a stronger clinical footprint.
The company plans to expand its commercial team, focusing on ENT practices that treat high volumes of chronic rhinitis patients. It will also support ongoing clinical research to generate long-term data that demonstrates durability and patient satisfaction.
Physician education will play a crucial role in this expansion. Neurent Medical intends to invest in training programs, workshops, and peer-to-peer engagement initiatives. These efforts will help ENT specialists understand the science behind NEUROMARK and integrate the treatment into their practice with confidence.
Addressing a Growing Global Need
Chronic rhinitis does not discriminate by geography. Patients across North America, Europe, and Asia report persistent nasal symptoms that reduce productivity and diminish overall well-being. Environmental factors, pollution, allergens, and lifestyle changes have contributed to rising incidence rates in many regions.
Neurent Medical sees an opportunity to respond to this global burden. By focusing on a targeted nerve-based approach, the company differentiates itself from pharmaceutical solutions that require continuous use. Patients often express frustration with daily medication regimens that fail to deliver lasting relief.
The NEUROMARK system provides a different pathway. It allows physicians to treat the root neural triggers in a single, controlled procedure. This model appeals to patients who want fewer ongoing interventions and more predictable outcomes.
Building Long-Term Clinical Evidence
Neurent Medical understands the importance of robust clinical validation. The company has conducted multiple studies to evaluate safety and effectiveness. These studies have shown promising results, including significant reductions in symptom scores and improvements in quality of life.
With Series C funding, the company plans to expand clinical trials and gather longer-term follow-up data. Strong evidence will support reimbursement discussions and encourage broader physician adoption. Healthcare providers increasingly demand data-driven proof before they incorporate new technologies into routine practice.
Neurent Medical aims to meet that expectation head-on. The company’s leadership recognizes that sustained growth requires not just innovation, but also transparency and measurable outcomes.
A Vision Beyond One Device
While NEUROMARK remains the company’s flagship product, Neurent Medical views its technology platform as a foundation for future development. The team continues to explore additional applications of targeted radiofrequency therapy within ENT and adjacent specialties.
This forward-looking approach demonstrates ambition beyond a single product cycle. The company wants to establish itself as a leader in nerve-targeted therapies that address chronic inflammatory conditions in minimally invasive ways.
By combining engineering expertise, clinical insight, and patient-centric design, Neurent Medical has positioned itself for sustained innovation. The €62.5 million funding round provides fuel for that journey.
Ireland’s Medtech Momentum Continues
Neurent Medical’s progress reflects the strength of Ireland’s broader medical technology sector. Over the past decade, the country has attracted multinational device manufacturers and fostered homegrown startups that compete on the global stage.
Galway, in particular, has cultivated a collaborative environment where engineers, clinicians, and entrepreneurs work closely together. Neurent Medical emerged from this ecosystem and benefited from access to talent, mentorship, and investment networks.
The Series C announcement reinforces Ireland’s reputation as a serious player in global medtech innovation. It shows that companies outside Silicon Valley or major U.S. biotech hubs can raise significant capital and lead in specialized therapeutic areas.
Looking Ahead
Neurent Medical now enters a critical growth phase. The company must execute its expansion strategy with discipline and clarity. It must scale operations while preserving product quality and clinical rigor.
Leadership has expressed confidence in the road ahead. The funding gives the company breathing room to invest strategically, strengthen partnerships, and refine its commercial approach.
Patients living with chronic rhinitis continue to search for better solutions. Neurent Medical aims to answer that call with a targeted therapy that moves beyond symptom management. The €62.5 million Series C round marks more than a financial milestone — it marks a step toward broader access, stronger evidence, and a renewed focus on improving everyday life for millions.
If Neurent Medical delivers on its promise, NEUROMARK could reshape how physicians treat chronic rhinitis worldwide.
Also Read – Top 10 Startup Pivot Stories